---------- Forwarded message ----------
From: HubMed - breast cancer <rssfwd@rssfwd.com>
Date: Sun, Aug 3, 2008 at 8:08 AM
Subject: Molecular targeted therapies for breast cancer treatment.
To: mesothelioma77@gmail.com
[1]Breast Cancer Res. 2008 Jul 24; 10(4): 211
Schlotter CM, Vogt U, Allgayer H, Brandt B
ABSTRACT: Targeting the oestrogen receptor, HER2 (human epidermal growth factor receptor 2) and vascular endothelial growth factor has markedly improved breast cancer therapy. New targeted therapeutic approaches to induction of apoptosis or inhibition of anti-apoptosis, cell cycle progression, signal transduction and angiogenesis are described. The molecular pathways and their inhibitory or repair mechanisms are discussed in the preclinical and clinical settings.
___
Source: http://www.hubmed.org/display.cgi?uids=18671839
--
~
Powered by [5]RssFwd, a service of [6]Blue Sky Factory, Inc
Links for Aseanface Humor
From: HubMed - breast cancer <rssfwd@rssfwd.com>
Date: Sun, Aug 3, 2008 at 8:08 AM
Subject: Molecular targeted therapies for breast cancer treatment.
To: mesothelioma77@gmail.com
[1]Breast Cancer Res. 2008 Jul 24; 10(4): 211
Schlotter CM, Vogt U, Allgayer H, Brandt B
ABSTRACT: Targeting the oestrogen receptor, HER2 (human epidermal growth factor receptor 2) and vascular endothelial growth factor has markedly improved breast cancer therapy. New targeted therapeutic approaches to induction of apoptosis or inhibition of anti-apoptosis, cell cycle progression, signal transduction and angiogenesis are described. The molecular pathways and their inhibitory or repair mechanisms are discussed in the preclinical and clinical settings.
___
Source: http://www.hubmed.org/display.cgi?uids=18671839
--
~
Powered by [5]RssFwd, a service of [6]Blue Sky Factory, Inc
Links for Aseanface Humor
Poems URL Links